Venous thromboembolism (VTE) is a major cause of both morbidity and mortality in patients
with cancer. Venous thromboembolism, which includes both deep vein thrombosis and …

Venous thromboembolism (VTE) is a common complication in patients with cancer and
portends a poor prognosis. Our understanding of the underlying pathophysiology of VTE in …

The epidemiology of cancer‐associated thrombosis (CAT) among uninsured and vulnerable
populations in the US is not well‐characterized. We performed a retrospective cohort study …

Active malignancy increases the risk of developing venous thromboembolism (VTE) by four-
to seven-fold. The risk of VTE, including deep vein thrombosis and pulmonary embolism, in …

Patients with cancer have an increased risk of venous thromboembolism (VTE). Comparing
tumor-specific VTE risk is complicated by factors such as surgery, disease stage, and …

Importance Identifying changes in epidemiologic patterns of the incidence and risk of cancer-
associated thrombosis (CAT), particularly with evolving cancer-directed therapy, is essential …

Venous thromboembolism is a leading cause of morbidity and mortality in patients with
active cancer who require anticoagulation treatment. Choice of anticoagulant is based on …

Venous disease is prevalent, undertreated, and frequently unrecognized. During the past
two decades, new treatment modalities have changed how venous disease is approached …

Venous thrombosis is a common adverse effect of modern therapy for acute lymphoblastic
leukemia (ALL). Prior studies to identify risks of thrombosis in pediatric ALL have been …

Purpose Studies in non-trauma populations have shown that Black patients have a higher
risk of venous thromboembolism (VTE) compared to other races. We sought to determine …